Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + SBRT in Locally Advanced HNSCC
NCT06673693Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Primary endpoint: Major Pathological Response at 4 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06673693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673693.